Twenty years' follow‐up of portal vein conduits in liver transplantation

Dmitriy Nikitin, Linda W. Jennings, Tariq Khan, Sugam Vasani, Richard Ruiz, Edmund Q. Sanchez, Srinath Chinnakotla, Marlon F. Levy, Robert M. Goldstein, Goran B. Klintmalm – 26 March 2009 – Portal vein problems remain a formidable challenge in liver transplantation. In select situations, a portal vein conduit can provide a solution. No long‐term results have been reported.

Incidence of prolonged length of stay after orthotopic liver transplantation and its influence on outcomes

Jenny O. Smith, Mitchell L. Shiffman, Martha Behnke, R. Todd Stravitz, Velimir A. Luketic, Arun J. Sanyal, Doug M. Heuman, Robert A. Fisher, Adrian H. Cotterell, Daniel G. Maluf, Marc P. Posner, Richard K. Sterling – 25 February 2009 – Orthotopic liver transplantation (OLT) is the only effective treatment for end‐stage liver disease. Although most patients do well and are discharged promptly, some require prolonged length of stay (PLOS). The prevalence of PLOS, associated factors, and their impact on survival are not well defined.

Usage and outcomes of deceased donor liver allografts with preprocurement injury from blunt trauma

Irma Laurentia Antonia Geenen, Meindert Nico Sosef, Albert Shun, Michael Crawford, James Gallagher, Simone Strasser, Michael Stormon, Geoff McCaughan, Deborah Jean Verran – 25 February 2009 – The use of extended criteria donors is an effective way of reducing the shortage of deceased donor organs. Evidence of significant liver trauma in a deceased donor usually rules out transplantation of the liver. The aim of this study was to evaluate the use and outcomes of donor livers with preprocurement trauma.

Minichromosome maintenance protein‐2–positive portal tract lymphocytes distinguish acute cellular rejection from hepatitis C virus recurrence after liver transplantation

Esther Unitt, William Gelson, Susan E. Davies, Nicholas Coleman, Graeme J. M. Alexander – 25 February 2009 – Hepatitis C virus (HCV) is a leading indication for liver transplantation worldwide, but graft infection with HCV frequently leads to hepatic fibrosis. Acute cellular rejection (ACR) can be difficult to distinguish confidently from HCV, even with histology, but accurate diagnosis is critical because treatment of ACR may accelerate HCV‐related graft injury.

Clinically relevant differences in the model for end‐stage liver disease and model for end‐stage liver disease–sodium scores determined at three university‐based laboratories of the same area

Xavier Xiol, Pere Gines, Lluis Castells, Jorge Twose, Alba Ribalta, Xavier Fuentes‐Arderiu, Santiago Rodriguez, Jose Castellote, Miquel Navasa, Roser Deulofeu – 25 February 2009 – The Model for End‐Stage Liver Disease (MELD) score is considered an objective and reliable measure of liver disease severity. However, the use of specific laboratory methodologies may introduce significant and clinically relevant variations into the score. It has been suggested that the incorporation of sodium into MELD (MELD‐Na) can provide a more accurate survival prediction than MELD alone.

Subscribe to